Stay updated on Lirentelimab in Eosinophilic Esophagitis Clinical Trial
Sign up to get notified when there's something new on the Lirentelimab in Eosinophilic Esophagitis Clinical Trial page.

Latest updates to the Lirentelimab in Eosinophilic Esophagitis Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page revision has been updated to v3.3.2, replacing the previous v3.3.1 entry.SummaryDifference0.0%

- Check21 days agoChange DetectedRevision: v3.3.1 replaces v3.2.0 as an administrative update; no substantive changes to study content, eligibility criteria, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check29 days agoChange DetectedRemoved the funding-disclaimer banner about potential delays and outdated information. This is an administrative change that does not alter the study details, enrollment, or outcomes.SummaryDifference0.2%

- Check43 days agoChange DetectedNo additions or deletions were detected on the page; the study details and eligibility criteria remain as published.SummaryDifference0.3%

- Check71 days agoChange DetectedCore content updated with a government funding notice and updated operating-status guidance; version updated from v3.1.0 to v3.2.0.SummaryDifference3%

- Check79 days agoChange DetectedThe page now announces Revision: v3.1.0 and removes several drug-safety topic sections (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs), signaling a rebranding or scope reduction without adding new topics.SummaryDifference0.3%

Stay in the know with updates to Lirentelimab in Eosinophilic Esophagitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lirentelimab in Eosinophilic Esophagitis Clinical Trial page.